The city of Chattanooga, Tennessee, currently has 30 active clinical trials seeking participants for Cancer research studies.
Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
NCT02194738
Recruiting
This ALCHEMIST trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been or will be removed by surgery. Studying the genes in a patient's tumor cells may help doctors select the best treatment for patients that have certain genetic changes.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/21/2024
Locations: Memorial Hospital, Chattanooga, Tennessee
Conditions: Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7
Register for Updates
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
NCT05774951
Recruiting
This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard endocrine therapy in patients with ER+/HER2 - early breast cancer with intermediate or high risk for disease recurrence who completed definitive locoregional therapy (with or without chemotherapy) and standard adjuvant endocrine therapy (ET) for at least 2 years and up to 5 years. The planned duration of treatment in either arm of the study is 60 months.
Gender:
All
Ages:
Between 18 years and 130 years
Trial Updated:
06/19/2024
Locations: Research Site, Chattanooga, Tennessee
Conditions: Breast Cancer, Early Breast Cancer
Register for Updates
Pan Tumor Rollover Study
NCT03899155
Recruiting
Main Objective of this study is to examine long-term safety of nivolumab monotherapy including combinations and other cancer therapies in various tumor types.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: Local Institution, Chattanooga, Tennessee
Conditions: Cancer
Register for Updates
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
NCT04873362
Recruiting
This is a Phase III, two-arm, randomized, double-blind placebo-controlled study in participants with HER2-positive primary breast cancer who have received preoperative chemotherapy and HER2-directed therapy, including trastuzumab followed by surgery, with a finding of residual invasive disease in the breast and/or axillary lymph nodes. As of June 4, 2024, this study is no longer accepting any newly screened participants.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/14/2024
Locations: Sarah Cannon Research Institute / Tennessee Oncology, Chattanooga, Tennessee
Conditions: Breast Cancer
Register for Updates
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
NCT06357533
Recruiting
The purpose of this study is to evaluate efficacy and safety of Dato-DXd in combination with rilvegostomig or rilvegostomig monotherapy compared with pembrolizumab monotherapy as a first line therapy in participants with locally advanced or metastatic non-squamous NSCLC with high PD-L1 expression (TC ≥ 50%) and without actionable genomic alterations.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/13/2024
Locations: Research Site, Chattanooga, Tennessee
Conditions: Non-Small Cell Lung Cancer
Register for Updates
Phase 2 Study of DKN-01 in Colorectal Cancer
NCT05480306
Recruiting
This is a Phase 2 randomized, open-label, two-part, multicenter study with a safety run-in to evaluate efficacy and safety of DKN-01 plus FOLFIRI/FOLFOX and bevacizumab versus standard of care (SOC) [FOLFIRI/FOLFOX and bevacizumab] as second-line treatment of advanced CRC patients.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/12/2024
Locations: Tennessee Oncology, Chattanooga, Tennessee
Conditions: Colorectal Cancer, Colorectal Adenocarcinoma, Colo-rectal Cancer, Colorectal Cancer Metastatic
Register for Updates
A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study
NCT03768063
Recruiting
This is an open-label, multicenter, extension study. Patients who are receiving clinical benefit from atezolizumab monotherapy or atezolizumab in combination with other agent(s) or comparator agent(s) during participation in a Genentech or Roche-sponsored study (the parent study), who are eligible to continue treatment and who do not have access to the study treatment locally, may continue to receive study treatment in this extension study following roll-over from the parent study.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/11/2024
Locations: Sarah Cannon Research Institute / Tennessee Oncology, Chattanooga, Tennessee
Conditions: Cancer
Register for Updates
A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer
NCT05645692
Recruiting
This study will evaluate the efficacy, safety, and pharmacokinetics of tobemstomig alone or in combination with tiragolumab compared with atezolizumab in participants with previously untreated, locally advanced or metastatic urothelial cancer (mUC) who are ineligible to receive a platinum containing chemotherapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/11/2024
Locations: Sarah Cannon Research Institute / Tennessee Oncology, Chattanooga, Tennessee
Conditions: Urothelial Cancer
Register for Updates
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
NCT05952557
Recruiting
This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard adjuvant endocrine therapy for patients with ER+/HER2- early breast cancer with intermediate-high or high risk for disease recurrence who completed definitive locoregional therapy (with or without chemotherapy). The planned duration of treatment in either arm within the study will be 7 years.
Gender:
All
Ages:
Between 18 years and 130 years
Trial Updated:
06/11/2024
Locations: Research Site, Chattanooga, Tennessee
Conditions: Breast Cancer, Early Breast Cancer
Register for Updates
ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)
NCT04829604
Recruiting
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients who were previously treated with T-DXd
Gender:
All
Ages:
18 years and above
Trial Updated:
06/10/2024
Locations: Research Site, Chattanooga, Tennessee
Conditions: HER2 Positive Metastatic Breast Cancer
Register for Updates
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
NCT05061550
Recruiting
The study is intended to assess the safety and efficacy of perioperative treatment with Durvalumab in combination with Oleclumab, Monalizumab or AZD0171 and platinum doublet chemotherapy (CTX); or Volrustomig in combination with platinum doublet chemotherapy or datopotamab deruxtecan (Dato-DXd) in combination with durvalumab and single agent platinum chemotherapy in participants with resectable, early-stage non-small cell lung cancer.
Gender:
All
Ages:
Between 18 years and 95 years
Trial Updated:
06/07/2024
Locations: Research Site, Chattanooga, Tennessee
Conditions: Non-small Cell Lung Cancer
Register for Updates
Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
NCT05611931
Recruiting
The purpose of this study is to evaluate the efficacy and safety of selinexor as a maintenance treatment in patients with p53 wt endometrial carcinoma (EC), who have achieved a partial response (PR) or complete response (CR) (per Response Evaluation Criteria in Solid Tumors version 1.1 [RECIST v 1.1]) after completing at least 12 weeks of platinum-based therapy. A total of 220 participants will be enrolled in the study and randomized in a 1:1 ratio to maintenance therapy with either selinexor or... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/04/2024
Locations: Chattanooga's Program in Women's Oncology, Chattanooga, Tennessee
Conditions: Endometrial Cancer
Register for Updates